• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 14.02
  • VXN 16.95
  • VXO 14.44
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

Acorda Therapeutics, Inc., a biotechnology company, develops therapies for multiple sclerosis, spinal cord injury, and other nervous system disorders. Its marketed products include Ampyra (dalfampridine), a potassium channel blocker for improving walking in patients with multiple sclerosis; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company?s pipeline also includes various products in development for the treatment, regeneration, and repair of the spinal cord and brain. Its preclinical products comprise remyelination programs that include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath in multiple sclerosis, neuregulins/glial growth factor 2, and remyelinating antibodies; and chondroitinase program, which develops second generation approaches to overcoming the proteoglycan matrix. Acorda Therapeutics sells its products through specialty sales force, managed care team, and contract pharmaceutical telesales organizations. The company was founded in 1995 and is based in Hawthorne, New York.

NO
     
ACOR (Acorda Therapeutics Inc)
Last Trade 1.69 Date 2/19/2020
Change % 4.33 % Price Change 0.07
Open 1.65 52 Week High 15.41
High 1.74 52 Week Low 1.49
Low 1.62 Type stock
Volume 594023 Average Volume 2608633
Prev Close 1.62 Stock Exchange NASDAQ
Bid 1.68 Ask 1.69
Bid Size 9 Ask Size 27
1st Yr Estimated EPS Growth 0.0703 2nd Yr Estimated EPS Growth
2 Years Forward Earning Yield 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 6.4713 Book Value Yield 3.9947
Buy Back Yield 1.0E-4 CAPE Ratio
Cash Return -1.0739 Cash Flow per Share -2.7167
Cash Flow Yield -1.677 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -3.5494 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue 1.4253 EV / Pre Tax Income
EV / Revenue 1.0477 EV / Total Asset 0.2521
Expected Dividend Growth Rate Free Cash Flow per Share -4.5564
Free Caash Flow Ratio Free Cash Flow Yield -2.8126
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -1.9228 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 0.250334 PB Ratio 10 Year Growth -0.300104
PB Ratio 3 Year Growth 1.311032 Cash Ratio 3 Year Average 342.8432
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average 95.117122 PE Ratio 10 Year Growth
PE Ratio 10 Year High 865.0 PE Ratio 10 Year Low 6.473958
PE Ratio 1 Year Avg 18.341618 PE Ratio 1 Year High 21.239437
PE Ratio 1 Year Low 14.15493 PE Ratio 3 Year Avg 18.442997
PE Ratio 5 Year Avg 213.947211 PE Ratio 5 Year High 865.0
PE Ratio 5 Year Low 14.15493 Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg 16.781626 Price Change 1 Month 0.79803
Price to Cash Ratio 0.618321 Price / EBITDA
Price to Sales Ratio 0.400032 Price to Sales Ratio 10 Year Growth -0.330302
Price to Sales Ratio 3 Year Avg 1.475777 Price to Sales Ratio 5 Year Avg 213.947211
Sale per Share 4.0497 Sales Yield 2.4998
Sustainable Growth Rate -0.5916 Tangible Book Value per Share -1.9052
Tangible Book Value per Share 3 year Avg -3.9192 Tangible Book Value per Share 5 year Avg -4.1436
Total Asset per Share 16.6503 Total Yield 1.0E-4
Working Capital per Share 2.3886 Working Capital per Share 3 Year Avg 5.8219
Working Capital per Share 5 Year Avg 5.5828 Beta 1.398917